


Amendments to the Claims:


A listing of the claims, which consists of the amendments to Claims 1, 8 and 99-110, is set forth below:

1 (currently amended): An inhibitor of a protein kinase $C\alpha$ ($PKC\alpha$), the inhibitor comprising


A-Ala-Arg-Arg-X-B-Hyd-C-D- (SEQ ID NO:1), where A =AcHN-,



X=any amino acid or amino acid mimetic; B=Ala or a diaminopropionic acid (Dap) derivative having the formula



Hyd=Phe, Leu or Ile; C=Arg or Lys; and D=Ala or a Dap derivative having the formula



wherein any of the amino acids can alternatively be an analogous amino acid mimetic.

2-6 (canceled)

7 (original): The inhibitor of claim 1, wherein the $PKC\alpha$ is a human $PKC\alpha$.


8 (currently amended): The inhibitor of claim 1, comprising

Applicant: David S. Lawrence


Appl'n. No.: 10/589,029

Filed: June 21, 2007


Page 25




(SEQ ID NO:2),




(SEQ ID NO:2),




(SEQ ID NO:2),



(SEQ ID NO:2),



(SEQ ID NO:2), or



(SEQ ID NO:2).

9-93 (canceled)

94 (previously presented): The inhibitor of claim 1, having an $IC_{50} < 50 \mu\text{M}$ for the $\text{PKC}\alpha$.


95 (previously presented): The inhibitor of claim 1, having an $IC_{50} < 10 \mu\text{M}$ for the $\text{PKC}\alpha$.

96 (previously presented): The inhibitor of claim 1, having an $IC_{50} < 1 \mu\text{M}$ for the $\text{PKC}\alpha$.

97 (previously presented): The inhibitor of claim 1, wherein the inhibitor has an IC_{50} for the $\text{PKC}\alpha < 0.1$ that of any other PKC isoform.

98 (previously presented): The inhibitor of claim 1, wherein the inhibitor has an IC_{50} for the $\text{PKC}\alpha < 0.01$ that of any other PKC isoform.

99 (currently amended): The inhibitor of claim 1, comprising



(SEQ ID NO:2).


100 (currently amended): The inhibitor of claim 1, consisting of

Applicant: David S. Lawrence

Appl'n. No.: 10/589,029


Filed: June 21, 2007

Page 27




(SEQ ID NO:2).

101 (currently amended): The inhibitor of claim 1, comprising




(SEQ ID NO:2).

102 (currently amended): The inhibitor of claim 1, consisting of




(SEQ ID NO:2).

103 (currently amended): The inhibitor of claim 1, comprising




(SEQ ID NO:2).

104 (currently amended): The inhibitor of claim 1, consisting of




(SEQ ID NO:2).


105 (currently amended): The inhibitor of claim 1, comprising




106 (currently amended): The inhibitor of claim 1, consisting of




107 (currently amended): The inhibitor of claim 1, comprising



108 (currently amended): The inhibitor of claim 1, consisting of




109 (currently amended): The inhibitor of claim 1, comprising



(SEQ ID NO:2).

110 (currently amended): The inhibitor of claim 1, consisting of



(SEQ ID NO:2).